AbbVie

acquisition merger arrows

Biotech

AbbVie ends development of IL-1 asset in ulcerative colitis

AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis after a phase 2 study revealed insufficient efficacy results.

Gabrielle Masson Jul 31, 2025 12:32pm

Fierce Pharma

AbbVie will continue to pursue external innovation for long-term

Jul 31, 2025 11:44am

Question

AbbVie in talks over $1B Gilgamesh buyout: report

Jul 31, 2025 7:48am

Three blocks displaying from left to right a person a handshake and another person

AbbVie pays $700M upfront for trispecific rival to J&J, Pfizer

Jul 10, 2025 9:01am

Graphic of two hands shaking under a red and purple light

AbbVie inks $2.1B Capstan buyout to enter in vivo CAR-T market

Jun 30, 2025 9:45am

abbvie

AbbVie taps oncology research org for aid running diverse trials

May 28, 2025 11:25am